The Cdk inhibitor p27 in human cancer: Prognostic potential and relevance to anticancer therapy

Isabel M. Chu, Ludger Hengst, Joyce M. Slingerland

Research output: Contribution to journalReview article

684 Scopus citations

Abstract

The cyclin-dependent kinase (Cdk) inhibitor p27 (also known as KIP1) regulates cell proliferation, cell motility and apoptosis. Interestingly, the protein can exert both positive and negative functions on these processes. Diverse post-translational modifications determine the physiological role of p27. Phosphorylation regulates p27 binding to and inhibition of cyclin-Cdk complexes, its localization and its ubiquitin-mediated proteolysis. In cancers, p27 is inactivated through impaired synthesis, accelerated degradation and by mislocalization. Moreover, studies in several tumour types indicate that p27 expression levels have both prognostic and therapeutic implications.

Original languageEnglish (US)
Pages (from-to)253-267
Number of pages15
JournalNature Reviews Cancer
Volume8
Issue number4
DOIs
StatePublished - Apr 1 2008

    Fingerprint

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this